0 415

Cited 8 times in

Ratio of phosphorylated HSP27 to nonphosphorylated HSP27 biphasically acts as a determinant of cellular fate in gemcitabine-resistant pancreatic cancer cells

 Dongxu Kang  ;  Hye Jin Choi  ;  Sujin Kang  ;  So Young Kim  ;  Yong-sic Hwang  ;  Suyeon Je  ;  Zhezhu Han  ;  Joo-Hang Kim  ;  Jae J. Song 
 CELLULAR SIGNALLING, Vol.27(4) : 807-817, 2015 
Journal Title
Issue Date
Animals ; Antimetabolites, Antineoplastic/pharmacology* ; Antimetabolites, Antineoplastic/therapeutic use ; Cell Line, Tumor ; Cell Survival/drug effects ; Deoxycytidine/analogs & derivatives* ; Deoxycytidine/pharmacology ; Deoxycytidine/therapeutic use ; Down-Regulation ; Drug Resistance, Neoplasm* ; Gene Expression Profiling ; HSP27 Heat-Shock Proteins/analysis ; HSP27 Heat-Shock Proteins/genetics ; HSP27 Heat-Shock Proteins/metabolism* ; Humans ; Male ; Mice, Inbred BALB C ; Mice, Nude ; NF-kappa B/metabolism ; Pancreas/drug effects ; Pancreas/metabolism ; Pancreas/pathology ; Pancreatic Neoplasms/drug therapy* ; Pancreatic Neoplasms/genetics ; Pancreatic Neoplasms/metabolism ; Pancreatic Neoplasms/pathology ; Phosphorylation
Gemcitabine ; Nonphosphorylated HSP27 ; Pancreatic cancer ; Phosphorylated HSP27
Gemcitabine has been used most commonly as an anticancer drug to treat advanced pancreatic cancer patients. However, intrinsic or acquired resistance of pancreatic cancer to gemcitabine was also developed, which leads to very low five-year survival rates. Here, we investigated whether cellular levels of HSP27 phosphorylation act as a determinant of cellular fate with gemcitabine. In addition we have demonstrated whether HSP27 downregulation effectively could overcome the acquisition of gemcitabine resistance by using transcriptomic analysis. We observed that gemcitabine induced p38/HSP27 phosphorylation and caused acquired resistance. After acquisition of gemcitabine resistance, cancer cells showed higher activity of NF-κB. NF-κB activity, as well as colony formation in gemcitabine-resistant pancreatic cancer cells, was significantly decreased by HSP27 downregulation and subsequent TRAIL treatment, showing that HSP27 was a common network mediator of gemcitabine/TRAIL-induced cell death. After transcriptomic analysis, gene fluctuation after HSP27 downregulation was very similar to that of pancreatic cancer cells susceptible to gemcitabine, and then in opposite position to that of acquired gemcitabine resistance, which makes it possible to downregulate HSP27 to overcome the acquired gemcitabine resistance to function as an overall survival network inhibitor. Most importantly, we demonstrated that the ratio of phosphorylated HSP27 to nonphosphorylated HSP27 rather than the cellular level of HSP27 itself acts biphasically as a determinant of cellular fate in gemcitabine-resistant pancreatic cancer cells.
Full Text
Appears in Collections:
1. College of Medicine (의과대학) > BioMedical Science Institute (의생명과학부) > 1. Journal Papers
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers
Yonsei Authors
Kim, Joo Hang(김주항)
Song, Jae Jin(송재진) ORCID logo https://orcid.org/0000-0001-8183-9550
Choi, Hye Jin(최혜진) ORCID logo https://orcid.org/0000-0001-5917-1400
사서에게 알리기


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.